| Zugriffe | |
|---|---|
| Ustekinumab for the treatment of moderate‐to‐severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open‐label CADMUS Jr study | 103 |
| Juni 2024 | Juli 2024 | August 2024 | September 2024 | Oktober 2024 | November 2024 | Dezember 2024 | |
|---|---|---|---|---|---|---|---|
| Ustekinumab for the treatment of moderate‐to‐severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open‐label CADMUS Jr study | 2 | 2 | 11 | 6 | 3 | 4 | 2 |
| Zugriffe | |
|---|---|
| 2020_Philipp_etal.pdf | 138 |
